TrialA Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Trial details
- Registry ID
- NCT03507790
- Phase
- Phase 2
CGTX
Cognition Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790 | Cognition Therapeutics | Phase 2 | Completed | 2024-05-29Actual |
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536 | Cognition Therapeutics | Phase 2 | Completed | 2023-04-26Actual |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415 | Cognition Therapeutics | Phase 2 | Completed | 2024-11-25Actual |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 | Cognition Therapeutics | Phase 2 | Active not recruiting | 2027-05-31Estimated |
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).NCT05893537 | Cognition Therapeutics | Phase 2 | Terminated | 2025-03-04Actual |
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Trial details
- Registry ID
- NCT04735536
- Phase
- Phase 2
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Trial details
- Registry ID
- NCT05225415
- Phase
- Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Trial details
- Registry ID
- NCT05531656
- Phase
- Phase 2
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Trial details
- Registry ID
- NCT05893537
- Phase
- Phase 2
Latest recorded trial changes
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656 · Cognition Therapeutics
Primary completion date changed
− Before
Apr 2027
+ After
31 May 2027
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
NCT05225415 · Cognition Therapeutics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Safety and Tolerability of CT1812
+ After
Measure: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)